Study of Escitalopram in the Treatment of Specific Phobia

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Connor, Kathryn M., M.D.
• Collaborator: Forest Laboratories
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Adults 18-65 years of age

• DSM-IV criteria for specific phobia according to the MINI

• For women of childbearing potential, a negative serum pregnancy test at screening

• Written informed consent

Exclusion Criteria:

• Any current primary DSM-IV diagnosis other than specific phobia

• History of DSM-IV substance abuse or dependence within the last months

• Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition

• Suicide risk or serious suicide attempt within the last year

• Clinically significant laboratory or EKG abnormality or unstable medical condition

• For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study

• Subjects needing concurrent use of psychotropic medications